Literature DB >> 24312823

Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Zoya Hojabri1, Mohammad Ahangarzadeh Rezaee, Mohammad Reza Nahaei, Mohammad Hossein Soroush, Morteza Ghojazadeh, Tahereh Pirzadeh, Mostafa Davodi, Mona Ghazi, Reza Bigverdi, Omid Pajand, Mohammad Aghazadeh.   

Abstract

PURPOSE: The antimicrobial activity of doripenem in comparison of imipenem, meropenem and ertapenem among Pseudomonas aeruginosa isolated from burn and Cystic Fibrosis (CF) patients were determined.
METHODS: Metallo-β-lactamase (MBL) genes in imipenem non susceptible P. aeruginosa isolates were detected using PCR method. The in vitro susceptibilities of doripenem, imipenem, meropenem and ertapenem were determined by Etests. MIC50 and MIC90 for corresponding antibiotics were determined individually in burn and CF isolates.
RESULTS: Among isolates which were resistant to imipenem, 16 isolates were positive for the bla IMP gene. All isolates had no bla VIM gene. All MBL producing isolates were excluded. MIC50/MIC90 of doripenem in CF and burn isolates were 0.75/>32 and >32/>32 mg/L respectively. The corresponding values for imipenem in CF and burn isolates were 2/>32 and >32/>32 mg/L, respectively.
CONCLUSION: The susceptibility rate of doripenem is higher than that of imipenem and meropenem among P.aeruginosa isolated from CF patients, whereas, there is no difference between the efficiency of doripenem and old carbapenems in non MBL producing P.aeruginosa isolates in burn patients.

Entities:  

Keywords:  Burn; Cystic fibrosis; Doripenem; Imipenem; Iran; Pseudomonas aeruginosa

Year:  2013        PMID: 24312823      PMCID: PMC3846057          DOI: 10.5681/apb.2013.020

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  17 in total

1.  Of Pseudomonas, porins, pumps and carbapenems.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

2.  In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.

Authors:  S Nomura; A Nagayama
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

3.  In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.

Authors:  M M Traczewski; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.

Authors:  H Pai; J Kim; J Kim; J H Lee; K W Choe; N Gotoh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 5.  Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Louis B Rice
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

6.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

7.  Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.

Authors:  Nagwa El Amin; Christian G Giske; Shah Jalal; Berit Keijser; Göran Kronvall; Bengt Wretlind
Journal:  APMIS       Date:  2005-03       Impact factor: 3.205

8.  Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.

Authors:  Daniel J Wolter; Ellen Smith-Moland; Richard V Goering; Nancy D Hanson; Philip D Lister
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

9.  Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

Authors:  Mariana Castanheira; Ronald N Jones; David M Livermore
Journal:  Diagn Microbiol Infect Dis       Date:  2009-02-26       Impact factor: 2.803

Review 10.  Doripenem.

Authors:  David L Paterson; Daryl D Depestel
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

View more
  7 in total

1.  Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Paul Shea; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

2.  Doripenem Treatment during Continuous Renal Replacement Therapy.

Authors:  M G Vossen; J M Wenisch; A Maier-Salamon; A Fritsch; K Saria; C Zuba; S Jilch; R Lemmerer; M Unger; U Jaehde; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Molecular epidemiology of Escherichia coli sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran.

Authors:  Z Hojabri; M Mirmohammadkhani; F Kamali; K Ghassemi; S Taghavipour; O Pajand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-27       Impact factor: 3.267

4.  MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.

Authors:  Cédric Bretonnière; Adeline Maitte; Jocelyne Caillon; Gilles Potel; David Boutoille; Cédric Jacqueline; Christophe Guitton
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

5.  Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of Pseudomonas aeroginosa in a Tertiary Care Hospital of North India.

Authors:  Arti Negi; Mridu Anand; Avinash Singh; Awadhesh Kumar; Chinmoy Sahu; Kashi Nath Prasad
Journal:  Indian J Crit Care Med       Date:  2017-10

6.  In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates.

Authors:  Tonny Loho; Ninik Sukartini; Dalima A W Astrawinata; Suzanna Immanuel; Diana Aulia; Ika Priatni
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-07-03       Impact factor: 2.471

7.  Emergence of colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran.

Authors:  Hamid Reza Goli; Mohammad Reza Nahaei; Mohammad Ahangarzadeh Rezaee; Alka Hasani; Hossein Samadi Kafil; Mohammad Aghazadeh
Journal:  Iran J Microbiol       Date:  2016-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.